News

Horizon Europe Cluster 2 Work Programme 2021-2022 published

Published on | 4 years ago

Programmes Culture and society

The 2021-2022 Work Programme of Cluster 2 - Culture, Creativity and Inclusive Society has been adopted by the European Commission and published. The Work Programme can be found on the Funding and Tenders Portal or on the Cluster 2 webpage on our website.

The 2021 calls of Cluster 2 will open on 22 June 2021 and close on 7 October 2021.

On 1 July, The European Commission will organize an online info day for Cluster 2 and the call topics of the 2021-2022 Work Programme will be presented. Additionally a brokerage event will be organized on 2 July. More information on these events can be found here.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1746 articles available search in articles 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.